Table 2 Univariate and multivariate analysis of HGS, clinical and pathologic factors in validation cohorts
Characteristic | CIT/GSE39582 CRC | TCGA CRC | Meta-validation | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Univariate | Multivariate | Univariate | Multivariate | Univariate | Multivariate | |||||||
HR (95% CI) | P-value | HR (95%CI) | P-value | HR (95% CI) | P-value | HR (95% CI) | P-value | HR (95% CI) | P-value | HR (95% CI) | P-value | |
HGS | 8.66 (4.37–17.17) | < 0.001 | 7.54 (3.78–15.06) | < 0.001 | 2.59 (1.08–6.25) | 0.04 | 2.59 (1.08–6.25) | 0.04 | 8.25 (3.09–22.03) | < 0.001 | 7.25 (2.72–19.29) | < 0.001 |
Age | 1.01 (0.99 –1.03) | 0.58 |  |  | 1.01 (0.98–1.04) | 0.37 |  |  | 0.97 (0.95–1.00) | 0.02 | 0.98 (0.96–1.00) | 0.05 |
Gender | 1.53 (0.898–2.62) | 0.12 |  |  | 1.56 (0.81–2.99) | 0.18 |  |  | 0.68 (0.39–1.16) | 0.15 |  |  |
TNM stage | 7.89 (1.11–55.91) | < 0.001 | 5.76 (0.81–41.12) | 0.08 | 1.83 (0.76–4.41) | 0.17 |  |  | 3.99 (1.24–12.80) | 0.01 | 3.73 (1.16–11.99) | 0.03 |
Tumor location | 1.08 (0.64–1.84) | 0.78 |  |  | 1.09 (0.59–2.04) | 0.78 |  |  | 1.30 (0.57–2.99) | 0.53 |  |  |
MMR status | 1.63 (0.70–3.82) | 0.25 |  |  | 0.64 (0.34–1.24) | 0.18 |  |  | 1.27 (0.42–3.86) | 0.67 |  |  |
CIMP status | 0.95 (0.44–2.02) | 0.89 |  |  |  |  |  |  | 0.91 (0.32–2.55) | 0.85 |  |  |
CIN status | 1.69 (0.75–3.81) | 0.20 |  |  |  |  |  |  |  |  |  |  |
TP53 mutation | 1.39 (0.78–2.48) | 0.27 |  |  |  |  |  |  |  |  |  |  |
KRAS mutation | 1.44 (0.86–2.40) | 0.16 |  |  | 1.02 (0.23–4.60) | 0.98 |  |  | 1.40 (0.50–3.94) | 0.52 |  |  |
BRAF mutation | 1.42 (0.57–3.58) | 0.45 |  |  |  |  |  |  | 1.72(0.61–4.81) | 0.30 |  |  |